{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026234","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.300440+00:00","generated_at":"2026-06-14T07:35:15.266743+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rani Therapeutics enters exclusive worldwide license with Celltrion for oral adalimumab biosimilar","bullets":["Rani obtains exclusive, worldwide, royalty-free license to Celltrion IP for oral adalimumab biosimilar via Rani's delivery technology.","Celltrion will exclusively supply adalimumab biosimilar to Rani, with limited alternative sourcing rights if supply is disrupted.","Rani has sole manufacturing, development, and commercialization rights; Celltrion gets right of first negotiation after Phase 1 data.","Celltrion may terminate if development milestones not met; Rani can terminate for convenience with notice.","No financial terms disclosed; agreement covers IP ownership and mutual indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026234","json":"https://secwatch.observer/filing/0000950170-23-026234.json","markdown":"https://secwatch.observer/filing/0000950170-23-026234.md","text":"https://secwatch.observer/filing/0000950170-23-026234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/0000950170-23-026234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/rani-20230601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:35:15.266743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54d8c9e9e0fbf2a987ccc606382f1acd443f0014","claim":"Rani Therapeutics Holdings, Inc. entered into License and Supply Agreement with Celltrion, Inc. valued at Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product; (effective 2023-06-01).","evidence_excerpt":"On June 1, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”). Under the License Agreement, Celltrion grants Rani an exclusive, worldwide, royalty-free license to certain intellectual property to make, use, sell, offer for sale, import and otherwise exploit an orally-administered therapeutic product using Rani’s oral delivery technology and Celltrion’s adalimumab biosimilar (“Product”) and to use certain information to support the manufacture, development and commercialization of Product.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/0000950170-23-026234-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Celltrion, Inc."},{"label":"Value","value":"Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product;"},{"label":"Effective","value":"2023-06-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}